Nearly one in 20 people who had a SARS-CoV-2 infection go on to experience myalgic encephalomyelitis/chronic fatigue syndrome ...

Shionogi’s S-892216 is being developed as a pre-exposure prophylaxis (PrEP) drug for Covid-19. Credit: seksan Mongkhonkhamsao ...

Jake Sullivan, the outgoing national security adviser, is asking a panel of outside experts to examine the government’s ...

The risk for myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is increased following COVID-19, according to study findings.

Researchers report the ability of tofacitinib to reduce infection risk with SARS-CoV-2 in individuals who are deficient in ...

Jay Bhattacharya Will Bring Transparency to NIH . Dr. Andrew Noymer is an epidemiologist and population health scientist who ...

Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) ...

In early December, health officials in the Democratic Republic of the Congo, or DRC, announced that an unknown illness had ...

Indeed, a recent study published in the journal Arteriosclerosis, Thrombosis, and Vascular Biology found a prolonged ...

Vaccination prior to COVID-19 infection does not significantly affect neurologic symptoms in patients with long COVID.

Historically, COVID-19 symptoms have been fevers or chills, cough, shortness of breath, cough, congestion or a runny nose, sore throat, loss of taste or smell, fatigue and body aches, headache, nausea ...

Researchers have identified a novel genetic risk factor for SARS-CoV-2 infection, providing new insights into the virus' ...